.png){kind=icon}
.png){kind=icon}
Return
Documented Use of Piperacillin–Tazobactam and Increased 1-Month Mortality in Healthcare-Associated Intra-Abdominal Infections
.png){kind=icon}
PRE
AI
C
N
N
S
P
DOI：10.1016/j.accpm.2026.101866.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Retrospective, propensity score–matched study • Inclusion of ICU patients with healthcare-associated intra-abdominal infection • Documented use of piperacillin–tazobactam is associated with increased 1-month mortality • Direct causality not proven; further studies are needed to confirm this signal
Journal
A
IF:
4.7
Papers:
114
Citations:
0
Organization
Cited Papers